Identification

Name
Mometasone
Accession Number
DB00764  (APRD00289)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Mometasone is a medium-potency synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. The anti-inflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

Structure
Thumb
Synonyms
  • (+)-Mometasone
  • Mometason
  • Mometasona
  • Mométasone
  • Mometasonum
External IDs
LAS-41002 / LAS41002 / Sch 32088
Product Ingredients
IngredientUNIICASInChI Key
Mometasone furoate04201GDN4R83919-23-7WOFMFGQZHJDGCX-ZULDAHANSA-N
Mometasone furoate monohydrateMTW0WEG809141646-00-6AQCCVUHZMIMSIB-HRVPQZBTSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AsmanexInhalant220 ug/1Respiratory (inhalation)Physicians Total Care, Inc.2006-03-09Not applicableUs
AsmanexInhalant110 ug/1Respiratory (inhalation)Merck Sharp & Dohme Limited2005-03-30Not applicableUs
AsmanexInhalant220 ug/1Respiratory (inhalation)Merck Sharp & Dohme Limited2005-03-30Not applicableUs
Asmanex HFAAerosol200 ug/1Respiratory (inhalation)Merck Sharp & Dohme Limited2014-04-25Not applicableUs
Asmanex HFAAerosol100 ug/1Respiratory (inhalation)Merck Sharp & Dohme Limited2014-04-25Not applicableUs
Asmanex TwisthalerPowder100 mcgRespiratory (inhalation)Merck Ltd.2015-04-08Not applicableCanada
Asmanex TwisthalerPowder200 mcgRespiratory (inhalation)Merck Ltd.2011-12-21Not applicableCanada
Asmanex TwisthalerPowder400 mcgRespiratory (inhalation)Merck Ltd.2011-12-21Not applicableCanada
Elocom CreamCream0.1 %TopicalMerck Ltd.1991-12-31Not applicableCanada
Elocom LotionLotion0.1 %TopicalMerck Ltd.1991-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mometasoneSpray, metered50 mcgNasalApotex Corporation2013-03-25Not applicableCanada
Mometasone FuroateOintment1 mg/gTopicalRebel Distributors2006-10-18Not applicableUs
Mometasone FuroateCream1 mg/gTopicalGlenmark Pharmaceuticals Inc.,Usa2008-05-28Not applicableUs
Mometasone FuroateCream1 mg/gTopicalProficient Rx LP2007-04-18Not applicableUs
Mometasone FuroateCream1 mg/gTopicalProficient Rx LP2008-05-28Not applicableUs
Mometasone FuroateSolution1 mg/mLTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2007-11-29Not applicableUs
Mometasone FuroateCream1 mg/gTopicalPerrigo New York Inc.2004-12-21Not applicableUs
Mometasone FuroateCream1 mg/gTopicalNu Care Pharmaceuticals,inc.2008-05-28Not applicableUs
Mometasone FuroateSolution1 mg/mLTopicalPerrigo New York Inc.2008-12-11Not applicableUs
Mometasone FuroateCream1 mg/gTopicalRebel Distributors2006-08-23Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MosaspraySpray, metered50 mcgNasalSandoz Canada IncorporatedNot applicableNot applicableCanada
Nasal Allergy and Congestion ReliefSpray, metered50 mcgNasalApotex CorporationNot applicableNot applicableCanada
Nasonex Allergy and CongestionSpray, metered50 mcgNasalMerck Ltd.Not applicableNot applicableCanada
International/Other Brands
Ecural (Essex pharma) / Elocom (Merck) / Elomet (Schering-Plough) / Eziwin (Intas) / mometAid (Progreś Laboratories) / Novasone (Schering-Plough)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DuleraMometasone furoate (100 ug/1) + Formoterol fumarate (5 ug/1)AerosolRespiratory (inhalation)Merck Sharp & Dohme Limited2010-06-22Not applicableUs
DuleraMometasone furoate (200 ug/1) + Formoterol fumarate (5 ug/1)AerosolRespiratory (inhalation)A S Medication Solutions2010-06-222017-06-20Us
DuleraMometasone furoate (200 ug/1) + Formoterol fumarate (5 ug/1)AerosolRespiratory (inhalation)Merck Sharp & Dohme Limited2010-06-22Not applicableUs
ZenhaleMometasone furoate (100 mcg)Aerosol, meteredRespiratory (inhalation)Merck Ltd.2011-03-10Not applicableCanada
ZenhaleMometasone furoate (200 mcg)Aerosol, meteredRespiratory (inhalation)Merck Ltd.2011-06-17Not applicableCanada
ZenhaleMometasone furoate (50 mcg)Aerosol, meteredRespiratory (inhalation)Merck Ltd.2011-06-20Not applicableCanada
Categories
UNII
8HR4QJ6DW8
CAS number
105102-22-5
Weight
Average: 427.361
Monoisotopic: 426.136464798
Chemical Formula
C22H28Cl2O4
InChI Key
QLIIKPVHVRXHRI-CXSFZGCWSA-N
InChI
InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,10S,11S,13R,14R,15S,17S)-1-chloro-14-(2-chloroacetyl)-14,17-dihydroxy-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES

Pharmacology

Indication

The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.

Structured Indications
Pharmacodynamics

Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. The clinical significance of these findings is unknown.

Mechanism of action

Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
UProgesterone receptor
agonist
Human
Absorption

Nasal spray is virtually undetectable in plasma

Volume of distribution
Not Available
Protein binding

98% to 99% (in a concentration range of 5 to 500 ng/mL).

Metabolism

Hepatic. Extensive metabolism to multiple metabolites. There are no major metabolites detectable in plasma. Upon in vitro incubation, one of the minor metabolites formed is 6ß-hydroxy-mometasone furoate. In human liver microsomes, the formation of the metabolite is regulated by cytochrome P-450 3A4.

Route of elimination
Not Available
Half life

5.8 hours

Clearance
Not Available
Toxicity

The potential for acute toxic effects following overdose with the mometasone inhaler is low. However, habitual overuse of the product can cause symptoms of steroid overload, including menstrual irregularities, acne, obesity, and muscle weakness. Single oral doses up to 8000 µg have been studied on human volunteers with no adverse events reported.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Mometasone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Mometasone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Mometasone.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mometasone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mometasone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Mometasone.Approved, Withdrawn
AldesleukinMometasone may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Mometasone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Mometasone.Experimental
AloglutamolThe bioavailability of Mometasone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Mometasone.Experimental
AluminiumThe bioavailability of Mometasone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Mometasone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Mometasone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Mometasone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Mometasone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Mometasone.Approved
AmiodaroneThe serum concentration of Mometasone can be increased when it is combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Mometasone.Approved, Investigational
Amphotericin BMometasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Mometasone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Mometasone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Mometasone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Mometasone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Mometasone.Approved, Investigational
AprepitantThe serum concentration of Mometasone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Mometasone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Mometasone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Mometasone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mometasone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Mometasone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Mometasone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Mometasone.Experimental
BendroflumethiazideMometasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Mometasone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mometasone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Mometasone.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Mometasone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Mometasone.Experimental
Bismuth SubcitrateThe bioavailability of Mometasone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Mometasone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Mometasone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mometasone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Mometasone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Mometasone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Mometasone.Experimental
BumetanideMometasone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Mometasone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Mometasone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Mometasone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideMometasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Mometasone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Mometasone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Mometasone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mometasone.Approved, Investigational
CeritinibMometasone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mometasone.Approved, Vet Approved
ChlorothiazideMometasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Mometasone can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneMometasone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Mometasone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Mometasone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Mometasone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Mometasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Mometasone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Mometasone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Mometasone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Mometasone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Mometasone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Mometasone.Investigational
CyclopenthiazideMometasone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Mometasone.Investigational
DaidzeinThe serum concentration of Mometasone can be increased when it is combined with Daidzein.Experimental
DanazolMometasone may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Mometasone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Mometasone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Mometasone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Mometasone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Mometasone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Mometasone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mometasone.Approved, Vet Approved
DienestrolThe serum concentration of Mometasone can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Mometasone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Mometasone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mometasone.Approved
DihydrotestosteroneMometasone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Mometasone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Mometasone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Mometasone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Mometasone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Mometasone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Mometasone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Mometasone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Mometasone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Mometasone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Mometasone.Approved
EquolThe serum concentration of Mometasone can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Mometasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Mometasone can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Mometasone can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Mometasone can be increased when it is combined with Estrone.Approved
Etacrynic acidMometasone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Mometasone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Mometasone.Experimental
Ethinyl EstradiolThe serum concentration of Mometasone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Mometasone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Mometasone.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Mometasone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Mometasone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Mometasone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Mometasone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Mometasone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mometasone.Approved
FenthionThe risk or severity of adverse effects can be increased when Mometasone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Mometasone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Mometasone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Mometasone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mometasone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Mometasone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Mometasone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Mometasone.Experimental
FluoxymesteroneMometasone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mometasone.Approved, Investigational
FosaprepitantThe serum concentration of Mometasone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Mometasone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideMometasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Mometasone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Mometasone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Mometasone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Mometasone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Mometasone is combined with GI-5005.Investigational
GLPG-0492Mometasone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Mometasone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Mometasone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Mometasone.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Mometasone is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Mometasone is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Mometasone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Mometasone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Mometasone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mometasone.Approved, Investigational
HydrochlorothiazideMometasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideMometasone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Mometasone can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Mometasone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Mometasone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Mometasone.Approved
IdelalisibThe serum concentration of Mometasone can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Mometasone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Mometasone.Approved
IndapamideMometasone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Mometasone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Mometasone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mometasone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Mometasone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Mometasone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Mometasone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Mometasone is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Mometasone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Mometasone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Mometasone.Withdrawn
ItraconazoleThe serum concentration of Mometasone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Mometasone.Experimental
KetoconazoleThe serum concentration of Mometasone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Mometasone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mometasone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Mometasone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Mometasone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Mometasone.Experimental
LopinavirThe serum concentration of Mometasone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Mometasone.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Mometasone is combined with Loxapine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Mometasone.Approved, Investigational
LumacaftorThe serum concentration of Mometasone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Mometasone.Approved, Investigational
MagaldrateThe bioavailability of Mometasone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Mometasone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Mometasone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Mometasone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Mometasone.Approved
Magnesium silicateThe bioavailability of Mometasone can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Mometasone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Mometasone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mometasone.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mometasone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mometasone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Mometasone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Mometasone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Mometasone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Mometasone.Approved
MesteroloneMometasone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Mometasone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Mometasone.Investigational, Withdrawn
MethallenestrilThe serum concentration of Mometasone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Mometasone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideMometasone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Mometasone.Approved, Vet Approved
MethyltestosteroneMometasone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Mometasone is combined with Metoclopramide.Approved, Investigational
MetolazoneMometasone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Mometasone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Mometasone is combined with Minaprine.Approved
MitotaneThe serum concentration of Mometasone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Mometasone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Mometasone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Mometasone.Experimental
MoxestrolThe serum concentration of Mometasone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mometasone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mometasone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Mometasone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Mometasone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Mometasone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Mometasone is combined with Nalidixic Acid.Approved, Investigational
NandroloneMometasone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateMometasone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Mometasone.Approved, Vet Approved
NefazodoneThe serum concentration of Mometasone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Mometasone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Mometasone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Mometasone.Approved
NevirapineThe serum concentration of Mometasone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Mometasone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Mometasone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Mometasone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mometasone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Mometasone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mometasone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Mometasone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Mometasone.Vet Approved
OxandroloneMometasone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Mometasone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Mometasone is combined with Oxolinic acid.Experimental
OxymetholoneMometasone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mometasone.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Mometasone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Mometasone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Mometasone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Mometasone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Mometasone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Mometasone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mometasone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Mometasone.Approved, Investigational
PhenytoinThe serum concentration of Mometasone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Mometasone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mometasone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Mometasone is combined with Pipemidic acid.Experimental
PiretanideMometasone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Mometasone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Mometasone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mometasone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Mometasone.Experimental
Polyestradiol phosphateThe serum concentration of Mometasone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideMometasone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Mometasone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Mometasone.Experimental, Investigational
PrimidoneThe serum concentration of Mometasone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Mometasone.Experimental
PromestrieneThe serum concentration of Mometasone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Mometasone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Mometasone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Mometasone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Mometasone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Mometasone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Mometasone can be increased when it is combined with Quinestrol.Approved
QuinethazoneMometasone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Mometasone is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Mometasone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Mometasone.Approved, Experimental, Investigational
RifabutinThe serum concentration of Mometasone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Mometasone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Mometasone can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Mometasone is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Mometasone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Mometasone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Mometasone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Mometasone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Mometasone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Mometasone.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Mometasone is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Mometasone.Approved
SaquinavirThe serum concentration of Mometasone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Mometasone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Mometasone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Mometasone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Mometasone.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Mometasone can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Mometasone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Mometasone.Investigational
St. John's WortThe serum concentration of Mometasone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololMometasone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Mometasone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mometasone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Mometasone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Mometasone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Mometasone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Mometasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Mometasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Mometasone is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Mometasone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Mometasone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Mometasone.Approved, Withdrawn
TelithromycinThe serum concentration of Mometasone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Mometasone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mometasone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Mometasone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Mometasone.Approved
TestosteroneMometasone may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateMometasone may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Mometasone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Mometasone.Approved
TiboloneThe serum concentration of Mometasone can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Mometasone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mometasone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mometasone.Approved
TorasemideMometasone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Mometasone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Mometasone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Mometasone is combined with Trichlorfon.Vet Approved
TrichlormethiazideMometasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Mometasone.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Mometasone.Approved
TromethamineThe bioavailability of Mometasone can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Mometasone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Mometasone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Mometasone.Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Mometasone is combined with Zoster vaccine.Approved
VoriconazoleThe serum concentration of Mometasone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinMometasone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Mometasone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mometasone.Approved, Investigational
ZeranolThe serum concentration of Mometasone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Mometasone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Mometasone.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Pui-Ho Yuen, Charles Eckhart, Teresa Etlinger, Nancy Levine, "Mometasone furoate monohydrate, process for making same and pharmaceutical compositions." U.S. Patent US6127353, issued April, 1988.

US6127353
General References
Not Available
External Links
Human Metabolome Database
HMDB14902
KEGG Drug
D08227
KEGG Compound
C07816
PubChem Compound
441335
PubChem Substance
46505288
ChemSpider
390090
ChEBI
6970
ChEMBL
CHEMBL1201404
Therapeutic Targets Database
DAP001042
PharmGKB
PA450541
HET
MOF
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Mometasone
ATC Codes
R03BA07 — MometasoneR01AD09 — MometasoneD07XC03 — MometasoneR03AK09 — Formoterol and mometasoneD07AC13 — Mometasone
AHFS Codes
  • 68:04.00 — Adrenals
  • 84:06.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (152 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentSpinal Cord Injuries (SCI)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentAllergic Rhinitis (AR)2
1CompletedTreatmentAsthma Bronchial1
1CompletedTreatmentAtopic Dermatitis (AD)1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentPsoriasis Vulgaris1
1, 2CompletedNot AvailableSeasonal Allergic Rhinitis (SAR)1
2CompletedTreatmentAcute Rhinosinusitis1
2CompletedTreatmentAirway Inflammation / Asthma Bronchial1
2CompletedTreatmentAsthma Bronchial6
2CompletedTreatmentChronic Rhinosinusitis1
2CompletedTreatmentPlaque Psoriasis1
2CompletedTreatmentPolyps, Nasal1
2CompletedTreatmentRhinitis, Allergic, Perennial1
2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)2
2Enrolling by InvitationTreatmentOesophagitis, Eosinophilic1
2Enrolling by InvitationTreatmentPolyps, Nasal1
2RecruitingTreatmentAsthma Bronchial1
2RecruitingTreatmentSickle Cell Disorders1
2SuspendedTreatmentPlaque Psoriasis1
2WithdrawnTreatmentAsthma Bronchial1
3Active Not RecruitingTreatmentAsthma Bronchial2
3CompletedNot AvailablePerennial Allergic Rhinitis (PAR)1
3CompletedSupportive CareCancer, Breast / Dermatologic Complications / Radiation Toxicity / Skin Reactions Secondary to Radiation Therapy1
3CompletedTreatmentAcute Rhinosinusitis1
3CompletedTreatmentAllergies / Conjunctivitis / Rhinitis / Rhinoconjunctivitis2
3CompletedTreatmentAsthma Bronchial5
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
3CompletedTreatmentOtitis Media With Effiusion1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)5
3CompletedTreatmentPerennial Allergic Rhinitis (PAR) / Rhinitis, Allergic, Perennial1
3CompletedTreatmentPolyps, Nasal2
3CompletedTreatmentRhinitis, Allergic, Perennial4
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)4
3Not Yet RecruitingTreatmentAllergic Rhinitis (AR)2
3RecruitingTreatmentMild Asthma1
3RecruitingTreatmentPolyps, Nasal1
3RecruitingTreatmentRhinitis, Allergic, Seasonal1
3Unknown StatusNot AvailableItching / Nasal Obstruction / Sneezing1
3Unknown StatusTreatmentMild to Moderate Persistent Allergic Rhinitis1
3WithdrawnTreatmentObstructive Sleep Apnea (Mild, Moderate, Severe) as Per Polysomnography1
4Active Not RecruitingTreatmentSeasonal Allergic Rhinitis (SAR)1
4CompletedNot AvailableAtopic Dermatitis (AD)1
4CompletedNot AvailableRhinitis, Allergic, Perennial and Seasonal1
4CompletedTreatmentAdenoidal Hypertrophy1
4CompletedTreatmentAdenoids1
4CompletedTreatmentAllergic Rhinitis (AR)2
4CompletedTreatmentAsthma Bronchial3
4CompletedTreatmentAsthma Bronchial / Rhinitis / Sinusitis1
4CompletedTreatmentObstructive Sleep Apnea (OSA) / Perennial Allergic Rhinitis (PAR) / Sleep Disorder1
4CompletedTreatmentPsoriasis1
4RecruitingHealth Services ResearchEarly Radiation Dermatitis1
4RecruitingTreatmentAsthma Bronchial / Sinusitis1
4RecruitingTreatmentChronic Rhinosinusitis Without Nasal Polyps1
4TerminatedTreatmentAdenoidectomy / Adenoids Hypertrophy / Nasal Obstruction1
4TerminatedTreatmentAsthma Bronchial2
4TerminatedTreatmentAsthma Bronchial / Rhinitis, Allergic, Seasonal1
4TerminatedTreatmentPerennial Allergic Rhinitis (PAR)1
4TerminatedTreatmentSeasonal Allergic Rhinitis (SAR)1
4Unknown StatusBasic SciencePolyps, Nasal1
4Unknown StatusTreatmentAsthma Bronchial1
4Unknown StatusTreatmentAsthma Bronchial / Polyps, Nasal / Sinusitis1
4Unknown StatusTreatmentPhimosis1
4Unknown StatusTreatmentVitiligo1
4WithdrawnTreatmentEnuresis / Obstructive Sleep Apnea (OSA) / Sleep Disordered Breathing (SDB)1
Not AvailableCompletedNot AvailableAllergic Rhinitis (AR)1
Not AvailableCompletedNot AvailableRhinitis, Allergic, Perennial / Rhinitis, Allergic, Seasonal1
Not AvailableCompletedNot AvailableSeasonal Allergic Rhinitis (SAR)1
Not AvailableCompletedOtherAsthma Bronchial1
Not AvailableNot Yet RecruitingNot AvailableAsthma in Children1
Not AvailableRecruitingNot AvailableAsthma Bronchial1
Not AvailableSuspendedTreatmentAsthma Bronchial / Rhinitis1

Pharmacoeconomics

Manufacturers
  • Schering corp sub schering plough corp
  • Altana inc
  • G and w laboratories inc
  • Glenmark generics inc usa
  • Taro pharmaceuticals usa inc
  • Tolmar inc
  • Nycomed us inc
  • Perrigo co
  • Perrigo new york inc
  • Schering corp
  • Schering plough healthcare products inc
  • Schering-Plough
Packagers
Dosage forms
FormRouteStrength
InhalantRespiratory (inhalation)110 ug/1
InhalantRespiratory (inhalation)220 ug/1
AerosolRespiratory (inhalation)100 ug/1
AerosolRespiratory (inhalation)200 ug/1
PowderRespiratory (inhalation)100 mcg
PowderRespiratory (inhalation)200 mcg
PowderRespiratory (inhalation)400 mcg
AerosolRespiratory (inhalation)
CreamTopical0.1 %
LotionTopical0.1 %
OintmentTopical0.1 %
CreamTopical1 mg/g
LotionTopical1 mg/g
LotionTopical1 mg/mL
OintmentTopical1 mg/g
SolutionTopical1 mg/mL
Spray, meteredNasal50 ug/1
Spray, meteredNasal50 mcg
CreamTopical.1 %
LotionTopical.1 %
Aerosol, meteredRespiratory (inhalation)
Prices
Unit descriptionCostUnit
Asmanex 120 Metered Doses 220 mcg/inh Aerosol 0.24 gm Inhaler230.27USD inhaler
Asmanex twisthaler 220 mcg #30131.47USD inhaler
Asmanex twisthaler 110 mcg #30121.76USD inhaler
Nasonex 50 mcg/act Suspension 50 mcg Nasal Spray116.82USD inhaler
Elocon 0.1% Lotion 60ml Bottle86.71USD bottle
Elocon 0.1% Cream 45 gm Tube79.13USD tube
Elocon 0.1% Ointment 45 gm Tube76.45USD tube
Mometasone Furoate 0.1% Solution 60ml Bottle64.99USD bottle
Mometasone Furoate 0.1% Cream 45 gm Tube50.96USD tube
Elocon 0.1% Lotion 30ml Bottle49.85USD bottle
Elocon 0.1% Ointment 15 gm Tube49.85USD tube
Elocon 0.1% Cream 15 gm Tube47.68USD tube
Mometasone Furoate 0.1% Ointment 45 gm Tube35.99USD tube
Mometasone Furoate 0.1% Solution 30ml Bottle32.99USD bottle
Mometasone Furoate 0.1% Cream 15 gm Tube29.99USD tube
Mometasone Furoate 0.1% Ointment 15 gm Tube19.19USD tube
Nasonex 50 mcg nasal spray6.37USD g
Elocon 0.1% cream2.69USD g
Mometasone furoate 0.1% cream1.42USD g
Elocom 0.1 % Cream0.7USD g
Elocom 0.1 % Ointment0.63USD g
Elocom 0.1 % Lotion0.47USD g
Pms-Mometasone 0.1 % Ointment0.35USD g
Ratio-Mometasone 0.1 % Ointment0.35USD g
Taro-Mometasone 0.1 % Ointment0.35USD g
Taro-Mometasone 0.1 % Lotion0.33USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5394868No1995-06-252012-06-25Us
CA2282360No2004-11-092018-03-16Canada
CA2091360No1997-04-082011-09-06Canada
US6127353Yes1998-04-032018-04-03Us
US6240918Yes1997-08-202017-08-20Us
US8173172Yes1998-09-172018-09-17Us
US6503537Yes1998-09-172018-09-17Us
US5829434Yes1996-05-032016-05-03Us
US6068832No1997-08-272017-08-27Us
US7067502No2000-05-212020-05-21Us
US7566705No2000-05-212020-05-21Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)218-220 °CNot Available
water solubilityPractically insoluble.Not Available
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00523 mg/mLALOGPS
logP2.81ALOGPS
logP3.5ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)12.48ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity110.29 m3·mol-1ChemAxon
Polarizability43.82 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9721
Caco-2 permeable+0.7845
P-glycoprotein substrateSubstrate0.7849
P-glycoprotein inhibitor INon-inhibitor0.7635
P-glycoprotein inhibitor IINon-inhibitor0.656
Renal organic cation transporterNon-inhibitor0.7753
CYP450 2C9 substrateNon-substrate0.852
CYP450 2D6 substrateNon-substrate0.9135
CYP450 3A4 substrateSubstrate0.8028
CYP450 1A2 substrateNon-inhibitor0.9383
CYP450 2C9 inhibitorNon-inhibitor0.8572
CYP450 2D6 inhibitorNon-inhibitor0.8429
CYP450 2C19 inhibitorNon-inhibitor0.8966
CYP450 3A4 inhibitorNon-inhibitor0.6761
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8898
Ames testNon AMES toxic0.8962
CarcinogenicityNon-carcinogens0.9393
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9124 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9254
hERG inhibition (predictor II)Non-inhibitor0.6092
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / Halogenated steroids / 3-oxo delta-1,4-steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Alpha-chloroketones / Secondary alcohols
show 7 more
Substituents
Progestogin-skeleton / 20-oxosteroid / Hydroxysteroid / Halo-steroid / 9-halo-steroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid
show 23 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, chlorinated steroid (CHEBI:6970)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Isogai M, Shimizu H, Esumi Y, Terasawa T, Okada T, Sugeno K: Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol. 1993 Feb;44(2):141-5. [PubMed:8439518]
  2. Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):S150-8. [PubMed:10518812]
  3. Smith CL, Kreutner W: In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998 Sep;48(9):956-60. [PubMed:9793625]
  4. Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H: Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. 2002 Aug 16;71(13):1523-34. [PubMed:12127907]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP: Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. [PubMed:15189034]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on December 14, 2017 11:10